In this study, we compared the bioNexia test (bioMérieux, Marcy-l'Étoile, France), a new immunochromatographic assay for the detection of Legionella pneumophila serogroup 1 in urine, with the BinaxNOW urinary antigen test (Alere, Waltham, Massachusetts, USA). After 15 min of incubation (in accordance with the manufacturers' instructions), the sensitivities and specificities were, respectively, 76.5% and 97.2% for the bioNexia test and 87.1% and 100% for the BinaxNOW test. After a prolonged incubation time of 60 min, the sensitivities and specificities increased to, respectively, 89.4% and 97.2% for the bioNexia test and 91.8% and 100% for the BinaxNOW test. When the tests were read after 15 min, the concentration of discrepant urine samples increased the sensitivities to 94.1% for both tests. In conclusion, we found that although the bioNexia test showed lower sensitivity for the detection of L. pneumophila antigen in nonconcentrated urine compared to the BinaxNOW test, a prolonged incubation time as well as the use of concentrated samples showed comparable sensitivities for both tests.KEYWORDS Legionella, Legionnaires' disease, urinary antigen test L egionnaires' disease (LD) is a severe pneumonia caused by Legionella spp., a Gram-negative bacillus found in many environments, including (man-made) aquatic systems and soil. Legionella spp. are responsible for 2 to 15% of all communityacquired pneumonias (1, 2). More than 90% of LD cases are caused by Legionella pneumophila, and 70 to 80% of these belong to serogroup type 1 (3, 4).In both Europe and the United States, the detection of Legionella antigen in urine is the most requested laboratory test for diagnosing legionnaires' disease (4). Most frequently used are immunochromatographic tests (ICTs). These tests are easy to use and are known for their relatively high sensitivity (70 to 90%) and specificity (95 to 100%), especially for L. pneumophila serogroup 1 (5-7). In addition, concentration of urine samples can increase sensitivity without affecting the specificity (3), although this preanalytical process requires some additional efforts. Heat treatment may be used to remove false-positive results caused by interfering antibodies (8). The aim of this study was to evaluate the bioNexia test (bioMérieux, Marcy-l'Étoile, France), a newly developed ICT for the qualitative detection of L. pneumophila serogroup 1 antigen in urine. When L. pneumophila serogroup 1 antigen is present in the sample, it binds to an anti-Legionella antibody that is conjugated to purple colloidal gold particles. The antigenantibody gold particle complex migrates up the membrane to the test line by capillary action. There it binds to the second anti-Legionella antibody present in the test line region. A purple-colored line is formed in the test line region. We compared the